

## research article

# Clinical impacts of copy number variations in B-cell differentiation and cell cycle control genes in pediatric B-cell acute lymphoblastic leukemia: a single centre experience

Klementina Crepinsek<sup>1,2</sup>, Gasper Marinsek<sup>1</sup>, Marko Kavcic<sup>2,3</sup>, Tomaž Prelog<sup>3</sup>, Lidija Kitanovski<sup>3</sup>, Janez Jazbec<sup>2,3</sup>, Marusa Debeljak<sup>1,2</sup>

<sup>1</sup> Clinical Institute for Special Laboratory Diagnostics, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia

<sup>2</sup> Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

<sup>3</sup> Department of Oncology and Haematology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia

Radiol Oncol 2022; 56(1): 92-101.

Received 7 September 2021

Accepted 5 November 2021

Correspondence to: Assist. Prof. Maruša Debeljak, Ph.D., Clinical Institute for Special Laboratory Diagnostics, University Children's Hospital, University Medical Centre Ljubljana, Vrazov trg 1, 1000 Ljubljana, Slovenia. E-mail: marusa.debeljak@kclj.si

Disclosure: No potential conflicts of interest were disclosed.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Background.** *IKZF1* gene deletions have been identified as a poor prognostic factor in pediatric B-cell acute lymphoblastic leukemia (B-ALL), especially in the presence of co-occurring deletions (*IKZF1*<sup>plus</sup> profile). This study aimed to determine the frequency of *IKZF1* deletions and deletions in other B-cell differentiation and cell cycle control genes, and their prognostic impact in Slovenian pediatric B-ALL patients.

**Patients and methods.** We studied a cohort of 99 patients diagnosed with B-ALL from January 2012 to December 2020 and treated according to the ALL IC-BFM 2009 protocol. Eighty-eight bone marrow or peripheral blood samples were analysed for copy number variations (CNVs) using the SALSA MLPA P335 ALL-*IKZF1* probemix.

**Results.** At least one CNV was detected in more than 65% of analysed samples. The most frequently altered genes were *PAX5* and *CDKN2A/B* (30.7%, 26.1%, and 25.0%, respectively). Deletions in *IKZF1* were present in 18.2% of analysed samples and were associated with an inferior 5-year event-free survival (EFS; 54.8% vs. 85.9%,  $p = 0.016$ ). The *IKZF1*<sup>plus</sup> profile was identified in 12.5% of the analysed samples, and these patients had an inferior 5-year EFS than those with deletions in *IKZF1* only and those without deletions (50.8% vs. 75.0% vs. 85.9%, respectively,  $p = 0.049$ ). Overall survival (OS) was also worse in patients with the *IKZF1*<sup>plus</sup> profile than those with deletions in *IKZF1* only and those without deletions (5-year OS 76.2% vs. 100% vs. 93.0%, respectively). However, the difference between the groups was not statistically significant.

**Conclusions.** Our results are in concordance with the results obtained in larger cooperative clinical trials. Copy number variations analysis using the SALSA MLPA kit is a reliable tool for initial diagnostic approach in children with B-ALL, even in smaller institutions in low- and middle-income countries.

Key words: B-acute lymphoblastic leukemia; *IKZF1* deletions; *IKZF1*<sup>plus</sup>; MLPA; pediatric; copy number variations (CNVs)

## Introduction

Improvements in risk stratification and new therapeutic approaches have dramatically improved

treatment outcomes in pediatric B-cell acute lymphoblastic leukemia (B-ALL). In developed countries, the overall survival for these patients is approaching 90%.<sup>1,2</sup> Nevertheless, some genetic

subtypes still imply poor outcomes, and 10–20% of patients experience a relapse that is often accompanied by treatment resistance and failure.<sup>3,4</sup> Therefore, the need for new diagnostic and prognostic markers remains of paramount importance.

In the previous years, deletions in the *IKZF1* gene have been identified as an important predictor of relapse in B-ALL.<sup>5–9</sup> *IKZF1* gene is located on chromosome 7p12.2 and consists of 8 exons, and of those, exons 2–8 are protein-coding. The gene codes for the transcription factor IKAROS, which regulates the expression of genes that control cell cycle progression and cell survival. It is involved in the development of all lymphoid lineages, especially in the differentiation of B-progenitor cells. Exons 4–6 encode four zinc finger DNA-binding domains that are essential for the tumour-suppressive function of IKAROS, and exon 8 encodes two zinc fingers that are responsible for the homo- or heterodimerization of IKAROS.<sup>10,11</sup> Genomic deletions in *IKZF1* occur in around 15% of pediatric B-ALL cases.<sup>5,6,8,12–14</sup> Their occurrence is exceptionally high in *BCR-ABL1*-positive (70%)<sup>15,16</sup> and *BCR-ABL1*-like (40%)<sup>13,17</sup> B-ALL, and have been associated with poor treatment response and an increased risk of relapse.<sup>5–9</sup> Deletions are most common in exons 4–7 or affect the whole gene, however, other less common lesions may also be present (e. g. deletions in exons 2–8, 2–7), and they are all associated with an unfavourable outcome in pediatric B-ALL.<sup>6,18</sup> Therefore, some study groups on B-ALL treatment have decided to include *IKZF1* deletion status into their risk stratification protocols. Others, however, did not, as there was hesitation on whether the prognostic impact of these deletions was strong enough to justify treatment intensification.<sup>14,19,20</sup>

Recently, another, minimal residual disease (MRD) dependent prognostic profile *IKZF1*<sup>plus</sup> with an immensely poor prognostic value was identified. This profile is defined by additional deletions in genes involved in cell differentiation and cell cycle regulation. *IKZF1* deletions that co-occur with deletions in *CDKN2A*, *CDKN2B*, *PAX5*, or the *PAR1* region (deletions of *CSF2RA* and *IL3RA*, but not *CRLF2*) in the absence of *ERG* deletions are associated with the worst event-free and overall survival.<sup>21</sup> This profile is already being used in the current AIEOP-BFM ALL 2017 trial as a high-risk criterion.<sup>20</sup> Copy number variations (CNVs) in some aforementioned genes (*PAX5*, *CDKN2A*, *CDKN2B*) also seem to be independently associated with poor prognosis, however, the results remain conflicting.<sup>19,22–25</sup> The inclusion of the CNV status of these genes may significantly improve risk stratification in B-ALL, but more studies are needed to elucidate their true prognostic effect.

Deletions in *IKZF1* are mostly observed in high-risk pediatric ALL subtypes. Many studies have confirmed the association of *IKZF1* deletions and *IKZF1*<sup>plus</sup> profile with poor treatment outcomes. In Slovenia, no studies have been done yet to determine the frequency of *IKZF1* deletions and CNVs in other cell differentiation and cell cycle regulation genes in pediatric B-ALL patients and treatment outcomes for these patients. Due to the importance of these alterations in the prognosis and choosing the best treatment approach, it is of great importance to determine their presence. Therefore, the study aimed to analyze bone marrow samples from Slovenian pediatric patients diagnosed with B-ALL from January 2012 to December 2020 for the presence of these CNVs and to determine their prognostic value.

Deletions in *IKZF1* are mostly observed in high-risk pediatric ALL subtypes. Many studies have confirmed the association of *IKZF1* deletions and *IKZF1*<sup>plus</sup> profile with poor treatment outcomes. In Slovenia, no studies have been done yet to determine the frequency of *IKZF1* deletions and CNVs in other cell differentiation and cell cycle regulation genes in pediatric B-ALL patients and treatment outcomes for these patients. Due to the importance of these alterations in the prognosis and choosing the best treatment approach, it is of great importance to determine their presence. Therefore, the study aimed to analyze bone marrow samples from Slovenian pediatric patients diagnosed with B-ALL from January 2012 to December 2020 for the presence of these CNVs and to determine their prognostic value.

## Patients and methods

### Patients and samples

In total, 99 children with B-ALL that were treated at the University Children's Hospital, University Medical Centre Ljubljana between January 2012 and December 2020 according to the ALL IC-BFM 2009 protocol were included in this study. Diagnoses were established following standard clinical, cytomorphological, and immunological criteria.

We obtained bone marrow samples for 92 patients as part of the diagnostic procedure before starting treatment. For 7 patients, bone marrow samples were not available, therefore, peripheral blood samples were obtained for the analysis. For four patients, there was no sufficient material available to perform the multiplex ligation-dependent probe amplification (MLPA) assay, 3 samples contained less than 40% of blasts and were excluded from analysis, and for an additional four, the assay failed due to poor sample quality. Therefore, data analysis was performed on 88 patient samples (82 bone marrow and 6 peripheral blood). The bone marrow samples contained  $77.4 \pm 16.7\%$  of blast in average, and for the peripheral blood samples this value was  $77.8 \pm 16.0\%$ . For survival analysis, patient samples from the year 2020 were excluded, due to the short follow-up period. Therefore, the survival analysis was carried out on 72 patients diagnosed between January 2012 and December 2019.

Informed consent was obtained from all subjects involved in the study, or their parents. The

**TABLE 1.** The demographic and clinical characteristics of Slovenian B-ALL patients included in the study

Characteristic	
Nr. of patients	99
<b>Sex</b>	
Male	54 (54.5%)
Female	45 (45.5%)
<b>Primary genetic abnormalities</b>	
<i>ETV6-RUNX1</i>	28 (28.3%)
<i>BCR-ABL1</i>	7 (7.1%)
<i>KMT2A</i> rearrangements	4 (4.0%)
<i>TCF3-PBX1</i>	4 (4.0%)
Hyperdiploidy	27 (27.3%)
Hypodiploidy	3 (3.0%)
iAMP21	2 (2.0%)
No recurrent abnormalities	24 (24.2%)
<b>Age at diagnosis</b>	
< 1	3 (3.0%)
1–5	57 (57.6%)
≥ 6	39 (39.4%)
<b>Risk group</b>	
Standard risk	17 (17.2%)
Intermediate risk	59 (59.6%)
High risk	23 (23.2%)
<b>FC- minimal residual disease</b>	
<b>Day 15</b>	
< 0.1%	35 (35.4%)
0.1–10%	48 (48.5%)
> 10%	13 (13.1%)
Unknown	3 (3.0%)
<b>Day 33</b>	
< 0.01%	73 (73.7%)
0.01–1%	20 (20.2%)
> 1%	3 (3.0%)
Unknown	3 (3.0%)

study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Republic of Slovenia (reference number KME 51/03/11).

### DNA extraction

Genomic DNA was extracted from bone marrow or peripheral blood samples using the FlexiGene

DNA Kit 250 (QIAGEN®, Hilden, Germany) according to the manufacturer's instructions. All samples were quantified using DS-11 FX+ Spectrophotometer (DeNovix, Wilmington, USA), and stored at 4°C. Before analysis, the DNA concentration was established at  $25 \pm 1$  ng/ $\mu$ L for the MLPA assay.

### Analysis of copy number alterations

DNA was analysed for copy number alterations using the SALSA MLPA P335 ALL-IKZF1 probemix, according to the manufacturer's instructions (MRC Holland, Amsterdam, the Netherlands). The P335 probemix allows for the detection of deletions and duplications in B-cell differentiation and cell cycle control genes (*IKZF1*, *CDKN2A/B*, *PAX5*, *EBF1*, *ETV6*, *BTG1*, and *RB1*), as well as in genes from the X/Y PAR1 region (*CRLF2*, *CSF2RA*, *SHOX*, *IL3RA*, and *P2RY8*). It also contains 13 reference probes that function as internal controls. Additionally, analysis for copy number alterations for the determination of *ERG* status was carried out on samples that carried deletions in *IKZF1* and at least one additional gene (namely *CDKN2A*, *CDKN2B*, *PAX5*, *CSF2RA*, and *IL3RA*) with the SALSA MLPA P327 iAMP21-*ERG* probemix. The P327 probemix is used for the detection of deletions, duplications or amplifications of specific sequences on chromosome 21, including intragenic deletions of *ERG*. It contains 59 MLPA probes that bind to several regions on chromosome 21, including the *ERG* gene, and 13 reference probes. DNA samples from healthy donors were used as controls.

MLPA reactions were carried out on a 96-well PCR thermocycler SimpliAmp Thermal Cycler (Applied Biosystems, Thermo Fisher, Massachusetts, USA), and the products were separated by capillary electrophoresis on an ABI-3500 genetic analyser (Applied Biosystems, Thermo Fisher, Massachusetts, USA). The resulting peak intensities were analysed using Coffalyser software (MRC-Holland) which performed the intrasample and intersample normalization of the peaks with the manufacturer's reference probes and normal control DNA, respectively. Values above 1.3 were considered as gain, between 1.3 and 0.75 normal, between 0.75 and 0.25 heterozygous loss, and below 0.25 homozygous loss.

### Statistical analysis

All statistical analyses were performed using SPSS 22.0 software (IBM Corp., Armonk, NY, USA).

Event-free survival (EFS; defined as the time between diagnosis and relapse or death) and overall survival (OS; defined as time between diagnosis and death or last follow-up) were analysed using the Kaplan-Meier method and the differences between multiple groups were analysed using the log-rank test. Multivariate analysis was performed using a Cox regression model, which was adjusted for other risk factors, namely sex, age at diagnosis, and risk group (HR vs. non-HR). Comparisons of categorical values were carried out using the Fischer's exact test, and for the comparison of numerical values, the Mann-Whitney U-test was used. The significance level for all the tests was 5% ( $p < 0.05$  was considered to be statistically significant).

## Results

### Study group

The cohort included 54 males and 45 females ( $N = 99$ ), with median age 4 years (range from 1 day to 23 years). Of these, 75 harboured recurrent genetic abnormalities (28 *ETV6-RUNX1*, 27 hyperdiploid karyotype, 7 *BCR-ABL1*, 4 *KMT2A* rearrangements, 4 *TCF3-PBX1*, 3 hypodiploid karyotype and 2 *iAMP21*), while no genetic alterations were identified in 24 patients (Figure 1). Based on age, white blood cell (WBC) count at diagnosis, blast cell counts on day 8, genetic abnormalities, and MRD at days 15 and 33, 17 patients were classified as standard risk (SR), 59 as intermediate risk (IR), and 23 as high risk (HR). The main patient characteristics are summed up in Table 1.

### Detection and analysis of *IKZF1* deletions by MLPA

Altogether, 92 patient samples and 5 controls were analysed by MLPA using the SALSA MLPA P335 ALL-*IKZF1* probemix. Four patient samples failed the MLPA analysis. Out of the remaining 88 samples, *IKZF1* deletions were found in 16 (18.2%). The most common was the deletion of the whole gene, which was observed in eight patients (50%), others were focal deletions. The second most common deletion was the deletion of exons 4–8, which was found in four patients (25%). This deletion was described as rare in other studies. Other deletions that were also detected in our cohort were the deletion of exons 2–8 (two patients; 12.5%), 4–7 and 5 (both found in one patient; 6.3%). Eleven patients with *IKZF1* deletion had additional deletions present, which put them in the *IKZF1*<sup>plus</sup> group. Of these, six




FIGURE 1. Prevalence of ALL subtypes in the Slovenian pediatric B-ALL cohort.




FIGURE 2. Primary genetic alterations in patients with *IKZF1* deletions.




FIGURE 3. The number of CNVs present in Slovenian B-ALL samples.

carried additional deletions in *CDKN2A*, *CDKN2B* and *PAX5*, three in *CDKN2A* and *CDKN2B*, one in only *CDKN2B*, and one had deletions in the *PAR1* region. *ERG* deletions were not found in any of these 11 samples.

The comparison of patient characteristics depending on *IKZF1* deletion is summarized in



**TABLE 2.** Patients' characteristics and response to treatment according to *IKZF1* deletion status in 91 Slovenian pediatric B-ALL patients

Characteristic	<i>IKZF1</i> status		
	No <i>IKZF1</i> deletion	<i>IKZF1</i> deletion only	<i>IKZF1</i> <sup>plus</sup>
<b>Nr. of patients</b>	72	5	11
<b>Sex</b>			
Male	34 (47.2%)	5 (100%)	9 (81.8%)
Female	38 (52.8%)	0 (0.0%)	2 (18.2%)
<b>Primary genetic abnormalities</b>			
ETV6-RUNX1	24 (33.3%)	0 (0.0%)	1 (9.1%)
BCR-ABL1	1 (1.4%)	2 (40.0%)	4 (36.4%)
KMT2A rearrangements	4 (5.6%)	0 (0.0%)	0 (0.0%)
TCF3-PBX1	3 (4.2%)	0 (0.0%)	1 (9.1%)
Hyperdiploidy	20 (27.8%)	2 (40.0%)	1 (9.1%)
Hypodiploidy	2 (2.8%)	0 (0.0%)	1 (9.1%)
iAMP21	1 (1.4%)	0 (0.0%)	0 (0.0%)
No recurrent abnormalities	18 (25.0%)	1 (20.0%)	3 (27.3%)
<b>Age at diagnosis</b>			
< 1	3 (4.2%)	0 (0.0%)	0 (0.0%)
1–5	41 (56.9%)	2 (40.0%)	5 (45.5%)
≥ 6	28 (38.9%)	3 (60.0%)	6 (54.5%)
<b>Risk group</b>			
Standard risk	13 (18.1%)	0 (0.0%)	0 (0.0%)
Intermediate risk	46 (63.9%)	2 (40.0%)	4 (36.4%)
High risk	13 (18.1%)	3 (60.0%)	7 (63.6%)
<b>FC- minimal residual disease</b>			
<b>Day 15</b>			
< 0.1%	30 (41.7%)	0 (0.0%)	1 (9.1%)
0.1–10%	33 (45.8%)	2 (40.0%)	6 (54.5%)
> 10%	6 (8.3%)	3 (60.0%)	4 (36.4%)
Unknown	3 (4.2%)	0 (0.0%)	0 (0.0%)
<b>Day 33</b>			
< 0.01%	56 (77.8%)	0 (0.0%)	8 (72.7%)
0.01–1%	13 (18.1%)	3 (60.0%)	2 (18.2%)
> 1%	2 (2.8%)	1 (20.0%)	0 (0.0%)
Unknown	1 (1.4%)	1 (20.0%)	1 (9.1%)

Table 2. Of the 16 patients that harboured *IKZF1* deletions, five patients had no recurrent genetic alterations. The presence of primary recurrent genetic abnormalities found in patients with *IKZF1* deletions is shown in Figure 2. *IKZF1* deletions were significantly more common in Ph<sup>+</sup> patients than in Ph<sup>-</sup> patients (6/7, 85.7% vs. 10/81, 12.3%,  $p$

= 0.0001), and so was the presence of the *IKZF1*<sup>plus</sup> profile (4/7, 57.1% vs. 7/81, 8.6%,  $p$  = 0.004).

The *IKZF1* deletions were significantly more common in males than in females ( $p$  = 0.0045), however, the presence of the *IKZF1*<sup>plus</sup> profile did not significantly differ between the sexes ( $p$  = 0.0607). Patients with *IKZF1* deletions were also older at diagnosis than those without deletions (median age 6 years, interquartile range (IQR) = 8 years vs. median age 4 years, IQR = 3.25 years,  $p$  = 0.052), and so were the patients with *IKZF1*<sup>plus</sup> profile in comparison to those who did not have this profile (median age 6 years, IQR = 8 years vs. median age 4 years, IQR = 4,  $p$  = 0.136), however the differences were not statistically significant. Patients with *IKZF1* deletions showed higher blast count values on the 8<sup>th</sup> day of chemotherapy treatment (median blast count 252 blasts/ $\mu$ L, IQR = 2018.5 blasts/ $\mu$ L vs. median blast cell count 17 blasts/ $\mu$ L, IQR = 192.5 blasts/ $\mu$ L,  $p$  = 0.0005), higher values of MRD on day 15 (median MRD15 6.15% IQR = 30.67% vs. median MRD15 0.184%, IQR = 1.24%,  $p$  = 0.0005), and 33 of treatment (median MRD33 0.001%, IQR = 0.15% vs. median MRD33 0.000%, IQR = 0.01%,  $p$  = 0.033) compared to those without deletions. Similarly, blast cell count and MRD15 values of patients with the *IKZF1*<sup>plus</sup> profile were higher compared to patients without the profile (median blast cell counts 224 blasts/ $\mu$ L, IQR = 2112 blasts/ $\mu$ L vs. median blast cell count 24 blasts/ $\mu$ L, IQR = 220 blasts/ $\mu$ L,  $p$  = 0.006; median MRD15 3.8%, IQR = 17.6% vs. median MRD15 0.24%, IQR = 2.23%,  $p$  = 0.030), while the difference was not significant for MRD33. The deletions were also more common in the HR group than in the IR (10/23, 43.5% vs. 6/52, 11.5%,  $p$  = 0.0032) and the SR group (10/23, 43.5% vs. 0/13, 0%,  $p$  = 0.0045). Patients in the HR group also exhibited the *IKZF1*<sup>plus</sup> profile more often than those in the IR (7/23, 30.4% vs. 4/52, 7.7%,  $p$  = 0.0160) and the SR group (7/23, 30.4% vs. 0/13, 0%,  $p$  = 0.0294).

In our cohort, 13 patients (14.8%) experienced an event (either relapse or death). Among these, four patients had no recurrent genetic alterations, three patients carried the *ETV6-RUNX1* fusion gene, two the *BCR-ABL1* fusion gene, two were hyperdiploid, one had a *KMT2A* rearrangement and one carried the *TCF3-PBX1* fusion gene. One patient was classified as SR, eight as IR and four as HR. In this group, five patients (5/13, 38.5%) carried an *IKZF1* deletion, and of those, four had additional deletions, but lacked the *ERG* deletions, which met the criteria for the *IKZF1*<sup>plus</sup> profile. The presence of *IKZF1* deletions and the *IKZF1*<sup>plus</sup> profile was

higher in the group of patients who experienced an event in comparison to those who did not, however the difference did not reach statistical significance (5/13 vs. 11/75,  $p = 0.055$  and 4/13 vs. 7/75,  $p = 0.053$ , respectively).

### Detection and analysis of other gene deletions and duplications by MLPA


The SALSA MLPA P335 ALL-IKZF1 probemix can detect deletions or duplications in the following B-cell differentiation and cell cycle control genes: *IKZF1*, *EBF1*, *CDKN2A/B*, *PAX5*, *ETV6*, *BTG1*, *RB1*, and in the PAR1 region (*SHOX* area, *CRLF2*, *CSF2RA*, *IL3RA* and *P2RY8* genes). At least one CNV was detected in 60 patient samples (68.2%). Of those, 60% carried three or more CNVs, 28.3% carried only one CNV, and 11.7% carried two CNVs (Figure 3).

The most common CNVs were those in the *PAX5* gene that were present in 30.7% of analysed samples, followed by *CDKN2A* and *CDKN2B* that were altered in 26.1% and 25.0% of analysed samples, respectively. In these genes, deletions were more common than amplifications. CNVs were also very common in the PAR1 region, 22.7% of analysed samples had at least one CNV present in this region, and in these genes, amplifications were observed more often than deletions. Detailed information about CNVs in all analysed genes are shown in Figure 4.

### Prognostic significance of *IKZF1* deletions

First, the patients were divided into two groups, a group with and a group without *IKZF1* deletions. The 5-year EFS was significantly worse for patients harbouring *IKZF1* deletions, compared to those without the deletions (54.8% vs. 85.9%,  $p = 0.016$ ) (Figure 5A). The 5-year OS was slightly worse as well for these patients, although the difference was not statistically significant (81.5% vs. 93.0%,  $p = 0.295$ ) (Figure 5B).

The 5-year EFS and OS were also compared between groups with no *IKZF1* deletions, with deletions in the *IKZF1* gene only and with the *IKZF1*<sup>plus</sup> profile. The difference in EFS between groups was statistically significant ( $p = 0.049$ ). Pairwise comparison showed that patients in group *IKZF1*<sup>plus</sup> had significantly poorer EFS in comparison to those in group with no *IKZF1* deletions (5-year EFS 50.8% vs. 85.9%,  $p = 0.016$ ), while the difference was not significant between other groups (Figure 6A).




**FIGURE 4.** Frequency of copy number variations: (A) Gene deletions in the cohort. (B) Gene amplifications in the cohort.

*BTG1* = *BTG* anti-proliferation factor 1; *CDKN2A/2B* = cyclin dependent kinase inhibitor 2A/2B; *CRLF2* = cytokine receptor-like factor 2; *CSF2RA* = colony-stimulating factor 2 receptor  $\alpha$  subunit; *EBF1* = early B-cell factor 1; *ETV6* = *ETS* variant 6; *IKZF1* = *IKAROS* family zinc finger 1; *IL3RA* = interleukin 3 receptor subunit  $\alpha$ ; *JAK2* = Janus kinase 2; *PAX5* = paired box 5; *P2RY8* = purinergic receptor P2RY8; *SHOX* = short-stature homeobox gene; *RB1* = *RB* transcriptional corepressor 1

The OS analysis between groups showed no differences between the groups (Figure 6B).


A multivariate Cox regression model was applied to this data to see, whether after adjusting for other relevant risk factors, *IKZF1* deletions profile retained a prognostic impact on event-free survival. We included the following variables in the model: sex, age at diagnosis, risk group (HR vs. nonHR) and the presence of *IKZF1* deletions. The overall model showed borderline significance ( $p = 0.05$ ). When each separate variable was inspected, it was observed that both sex and the presence of the *IKZF1* deletions showed a certain trend (males having poorer survival than females (HR = 1.44), and those with the *IKZF1* deletions having poorer survival than those without the deletions (HR = 1.15)), however, they did not reach significance ( $p = 0.072$  and  $p = 0.078$ , respectively). Similar results were obtained when this analysis was applied for the *IKZF1*<sup>plus</sup> profile. This can most likely be attributed to the small sample size of our sample for survival analysis.



**FIGURE 5. (A)** Event-free survival in patients with or without *IKZF1* deletions (5-year event-free survival [EFS] 54.8% vs. 85.9%,  $p = 0.016$ ). **(B)** Overall survival in patients with or without *IKZF1* deletions (5-year overall survival [OS] 81.5% vs. 93.0%,  $p = 0.295$ ).

We further looked at the group of patients, classified as non-high risk (either SR or IR). In this group, six patients carried the *IKZF1* deletions, and of those, two patients experienced an event (2/6, 33.3%), and among the patients without the deletions, seven experienced an event (7/59, 11.9%) ( $p = 0.1907$ ). The 5-year EFS for those without the deletions was 83.6%, while it was only 50% for those with the deletion. Once again, there is a cer-

tain trend to be seen, however, the difference was not statistically significant ( $p = 0.114$ ). We also examined patients with the *IKZF1*<sup>plus</sup> profile in the non-HR group. The frequency of events was higher amongst the patients with the profile compared to those without it (2/4, 50% vs. 7/61, 11.5%,  $p = 0.0890$ ), and their EFS was poorer, although not significantly (50.0% vs. 83.7%,  $p = 0.087$ ).



**FIGURE 6. (A)** Event-free survival in patients without *IKZF1* deletions, with *IKZF1* deletions only, and those with the *IKZF1*<sup>plus</sup> profile (5-year EFS 85.9% vs. 75.0% vs. 50.8%,  $p = 0.049$ ). **(B)** Overall survival in patients without *IKZF1* deletions, with *IKZF1* deletions only and those with the *IKZF1*<sup>plus</sup> profile (5-year OS 93.0% vs. 100% vs. 76.2%,  $p = 0.290$ ).

## Discussion

Various alterations in genes involved in cell differentiation and cell cycle regulation are a hallmark of B-ALL. The role of deletions in the *IKZF1* gene in B-ALL has previously been described as very prognostically revealing and predictive for relapse.<sup>8,21</sup> Due to their association with poorer treatment outcomes, it is important to detect them to adjust the treatment protocol accordingly. Moreover, alterations in other genes, such as *PAX5* and *CDKN2A/2B*, are also often present. However, information regarding their prognostic impact is still rather ambiguous<sup>19,22,23,26</sup>, therefore, more studies need to be carried out to define their true value for patient risk stratification.

Our study was carried out on a smaller (88 patients), yet consecutive, unselected, and well-controlled population of pediatric patients with B-ALL. This is the first report about CNVs in cell differentiation and cell cycle regulation genes in Slovenian pediatric B-ALL patients. In our cohort, *IKZF1* deletions were identified in 18.2% of analysed samples. This is in concordance with reports of *IKZF1* deletions ranging from 10.7 to 15.9% in other studies that analysed unselected cohorts.<sup>6,8,12–14,21</sup> The *IKZF1* deletions were more common in the HR group when compared to the IR and SR groups, as was also shown in the study done by Dörge *et al.*<sup>6</sup> Six out of seven (86%) patients with the *BCR-ABL1* translocation also carried deletions in the *IKZF1* gene, four of those had the *IKZF1*<sup>plus</sup> profile. As it was previously described, these deletions are very commonly, however not exclusively, present in *BCR-ABL1* ALL.<sup>12,15,16,21</sup> Some studies excluded patients with the *BCR-ABL1* translocation and determined the *IKZF1* status only in the *BCR-ABL1*-negative patients. These studies reported frequencies of *IKZF1* deletions from 9.4 to 16%.<sup>7,27–30</sup> Our results show that 12.3% of patients without *BCR-ABL1* in this cohort carried *IKZF1* deletions, which is again similar to previously published results.

The most common *IKZF1* deletion in our cohort was, as was also reported by other studies, the deletion of the whole gene (50%). Interestingly, however, the second most common deletion was that of exons 4–8 (25%), whereas this deletion was described as rare in other studies. The second most common deletion reported by other groups was that of exons 4–7<sup>6,8,18,31</sup> which results in a dominant-negative isoform (IK6). This deletion occurred in only one patient in our cohort. Nevertheless, all *IKZF1* deletions, including the rare ones, have

an important prognostic impact.<sup>18</sup> Therefore, all should be considered when selecting the appropriate treatment.

In our cohort, *IKZF1* deletions and the *IKZF1*<sup>plus</sup> profile were more common amongst males and were associated with higher blast values on day 8 of chemotherapy, higher values of MRD15 and MRD33, and were more often found in the HR group. The presence of *IKZF1* deletions and the *IKZF1*<sup>plus</sup> profile was higher amongst the patients who experienced an event (relapse or death) than those who did not, albeit this difference was not significant. Two of the patients who carried these deletions and experience a relapse also had the *BCR-ABL1* fusion gene, which placed them in the HR group. However, three others with these deletions and an event did not exhibit genetic alterations that would predict a poorer outcome – one patient carried the *ETV6-RUNX1* fusion, one was hyperdiploid and one had no recurrent genetic abnormalities. This shows that alterations in cell differentiation and cell cycle regulation genes may play a crucial role in disease development even in patients with primary genetic alterations that are thought to be favourable, which is in concordance with reports of these deletions being an independent prognostic factor.<sup>6</sup>

Previously published studies have shown a poorer event-free and overall survival of patients with *IKZF1* deletions in comparison to those without such aberrations<sup>6,8,12,14,16,30</sup>, and Stanulla *et al.* discovered that patients with additional mutations in certain genes that define the *IKZF1*<sup>plus</sup> profile have even more dismal outcomes.<sup>21</sup> Our study similarly confirmed the inferior event-free survival for patients with *IKZF1* deletions and the *IKZF1*<sup>plus</sup> profile, however, the overall survival did not significantly differ between the groups. After adjusting for confounding factors, our data did not confirm the independent prognostic role of the *IKZF1* deletions, as well as *IKZF1*<sup>plus</sup>, on EFS. However, the trend of poorer EFS in patients with the *IKZF1* deletions and the *IKZF1*<sup>plus</sup> profile was observed. These discrepancies, as well as the high proportion of males presenting with the *IKZF1* mutations, are most likely the result our small sample size and short follow-up duration. When inspecting non-high-risk patients with the *IKZF1*<sup>plus</sup> profile, the relative frequency of events among the patients with the profile was higher, and there was a trend of poorer EFS for these patients. The dismal outcomes for patients with the *IKZF1*<sup>plus</sup> profile have previously been confirmed by other studies, and this profile is currently already being used in cer-



tain treatment protocols<sup>20</sup>, and more are likely to follow.

The CNV analysis of other genes showed that the most common alterations were in the *PAX5* gene (30.7%), *CDKN2A*, and *CDKN2B* (26.1% and 25.0%, respectively). However, deletions in *CDKN2A/2B* were more common than deletions in *PAX5* which was also observed by Öfverholm *et al.*<sup>31</sup> and Mullighan *et al.*<sup>9</sup> Deletions in *PAX5* have previously been reported as much more common than intragenic amplifications in this gene, and the latter have mostly been reported only in isolated cases.<sup>31-34</sup> However, more recently, Schwab *et al.*<sup>23</sup> showed that *PAX5* amplifications occur in around 1% of B-ALL cases, out of which 40% experienced a relapse, suggesting that these alterations may play an important role in leukemogenesis. Interestingly, in our cohort, the amplifications were even more common, as they occurred in 10.2% of all B-ALL cases. Out of 27 patients with CNVs in *PAX5*, 9 (33.3%) carried amplifications. As already suggested by Schwab *et al.*<sup>23</sup>, more studies need to be conducted to evaluate the prognostic impact of *PAX5* amplifications. The *PAX5* deletions were also more frequent in our cohort (20.5%) than previously described (10%).<sup>35,36</sup> Amongst the samples with *PAX5* deletion, a sizable amount (61.1%) also carried the *CDKN2A/2B* deletions. The frequent co-occurrence of these deletions has previously been described by Kim *et al.*<sup>37</sup>

In our cohort, amplifications in the *PAR1* region were observed quite frequently. Altogether, 17 patients (19.3%) had at least one gene amplification in this region. This is due to the fact that our cohort is unselected, and therefore also includes patients with hyperdiploidy. In hyperdiploidy, gains in the X chromosome are very common (present in 70% of hyperdiploid childhood B-ALL cases)<sup>38</sup>, and indeed, 14 out of our 17 patients with amplifications in *PAR1* had a hyperdiploid karyotype. This karyotype is associated with a favourable outcome. However, the hyperdiploid patients in our cohort did not have a significantly better 5-year EFS, and the same was seen for the patients with amplifications in the *PAR1* region that were identified with MLPA. Two patients carried deletions in this region (namely in *CSF2RA*, *IL3RA* and *P2RY8* genes), which resulted in the formation of the *P2RY8-CRLF2* fusion gene. This was confirmed with fluorescence *in situ* hybridization. While the *P2RY8-CRLF2* fusion is associated with a poorer treatment response and outcomes<sup>39</sup>, the two patients in our cohort did not experience an event.

Despite the limitations of our study due to a lower number of analyzed samples and relatively short

follow-up period, it produced results that are in concordance with the results obtained in larger cooperative clinical trials. We have shown that it is possible to provide comparable results regarding the presence of certain CNVs and their prognostic value in pediatric B-ALL patients even within a single-center experience. This study is only a starting point for the more comprehensive screening of patients diagnosed with B-ALL in Slovenia that we have planned for the future and will enable us to better evaluate and treat these patients.

## Acknowledgments

The research was supported by the Slovenian Research Agency (ARRS) grant number P3-0343.

## References

1. Roberts KG, Reshmi SC, Harvey RC, Chen IM, Patel K, Stonerock E, et al. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the children's oncology group. *Blood* 2018; **132**: 815-24. doi: 10.1182/blood-2018-04-841676
2. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. *J Clin Oncol* 2012; **30**: 1663-9. doi: 10.1200/JCO.2011.37.8018
3. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. *CA Cancer J Clin* 2014; **64**: 83-103. doi: 10.3322/caac.21219
4. Einsiedel HG, Von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group 87. *J Clin Oncol* 2005; **23**: 7942-50. doi: 10.1200/JCO.2005.01.1031
5. Olsson L, Ivanov Öfverholm II, Norén-Nyström U, Zachariadis V, Nordlund J, Sjögren H, et al. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 1993. *Br J Haematol* 2015; **170**: 847-58. doi: 10.1111/bjh.13514
6. Dörge P, Meissner B, Zimmermann M, Möricke A, Schrauder A, Bouquin JP, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. *Haematologica* 2013; **98**: 428-32. doi: 10.3324/haematol.2011.056135
7. Asai D, Imamura T, Suenobu S, Saito A, Hasegawa D, Deguchi T, et al. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. *Cancer Med* 2013; **2**: 412-9. doi: 10.1002/cam4.87
8. Kuiper RP, Waanders E, Van Der Velden VHJ, Van Reijmersdal SV, Venkatachalam R, Scheijen B, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. *Leukemia* 2010; **24**: 1258-64. doi: 10.1038/leu.2010.87
9. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. *N Engl J Med* 2009; **360**: 470-80. doi: 10.1056/NEJMoa0808253
10. Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S, et al. The *ikaros* gene is required for the development of all lymphoid lineages. *Cell* 1994; **79**: 143-56. doi: 10.1016/0092-8674(94)90407-3

11. Molnar A, Wu P, Largespada DA, Vortkamp A, Scherer S, Copeland NG, et al. The Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA binding proteins, highly conserved in human and mouse. *J Immunol* 1996; **156**: 585-92. PMID: 8543809
12. Yang YL, Hung CC, Chen JS, Lin KH, Jou ST, Hsiao CC, et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan. *Cancer Sci* 2011; **102**: 1874-81. doi: 10.1111/j.1349-7006.2011.02031.x
13. Van Der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal S V., Russell LJ, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. *Blood* 2013; **122**: 2622-9. doi: 10.1182/blood-2012-10-462358
14. Moorman A V., Enshaei A, Schwab C, Wade R, Chilton L, Elliott A, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. *Blood* 2014; **124**: 1434-44. doi: 10.1182/blood-2014-03-562918
15. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. *Nature* 2008; **453**: 110-14. doi: 10.1038/nature06866
16. Van Der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. *Blood* 2014; **123**: 1691-8. doi: 10.1182/blood-2013-06-509794
17. Roberts KG. The biology of Philadelphia chromosome-like ALL. *Best Pract Res Clin Haematol* 2017; **30**: 212-21. doi: 10.1016/j.beha.2017.07.003
18. Boer JM, Van Der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, De Groot-Kruseman HA, et al. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study. *Leukemia* 2016; **30**: 32-38. doi: 10.1038/leu.2015.199
19. Steeghs EMP, Boer JM, Hoogkamer AQ, Boeree A, de Haas V, de Groot-Kruseman HA, et al. Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia. *Sci Rep* 2019; **9**: 1-11. doi: 10.1038/s41598-019-41078-4
20. Stanulla M, Cavé H, Moorman A V. IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker? *Blood* 2020; **135**: 252-60. doi: 10.1182/blood.2019000813
21. Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, et al. IKZF1 plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia. *J Clin Oncol* 2018; **36**: 1240-9. doi: 10.1200/JCO.2017.74.3617
22. Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. *Nat Genet* 2019; **51**: 296-307. doi: 10.1038/s41588-018-0315-5
23. Schwab C, Nebral K, Chilton L, Leschi C, Waanders E, Boer JM, et al. Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia? *Blood Adv* 2017; **1**: 1473-7. doi: 10.1182/bloodadvances.2017006734
24. Zhang W, Kuang P, Liu T. Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis. *Ann Med* 2019; **51**: 28-40. doi: 10.1080/07853890.2018.1564359
25. Carrasco Salas P, Fernández L, Vela M, Bueno D, González B, Valentín J, et al. The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia. *Pediatr Hematol Oncol* 2016; **33**: 415-22. doi: 10.1080/08880018.2016.1251518
26. Zhang W, Kuang P, Liu T. Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis. *Ann Med* 2019; **51**: 28-40. doi: 10.1080/07853890.2018.1564359
27. Yamashita Y, Shimada A, Yamada T, Yamaji K, Hori T, Tsurusawa M, et al. IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR-ABL1-negative high-risk B-cell precursor acute. *Pediatr Blood Cancer* 2013; **60**: 1587-92. doi: 10.1002/pbc
28. Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter V, et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? *Haematologica* 2013; **98**: 1226-31. doi: 10.3324/haematol.2012.075432
29. Clappier E, Gardel N, Bakkus M, Rapion J, De Moerloose B, Kastner P, et al. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951. *Leukemia* 2015; **29**: 2154-61. doi: 10.1038/leu.2015.134
30. Vrooman LM, Blonquist TM, Harris MH, Stevenson KE, Place AE, Hunt SK, et al. Refining risk classification in childhood b acute lymphoblastic leukemia: results of DFCl ALL consortium protocol 05-001. *Blood Adv* 2018; **2**: 1449-58. doi: 10.1182/bloodadvances.2018016584
31. Öfverholm I, Tran AN, Heyman M, Zachariadis V, Nordenskjöld M, Nordgren A, et al. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols. *Leukemia* 2013; **27**: 1936-9. doi: 10.1038/leu.2013.92
32. Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, et al. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. *Genes Chromosom Cancer* 2010; **49**: 1104-13. doi: 10.1002/gcc
33. Schwab CJ, Chilton L, Morrison H, Jones L, Al-Shehhi H, Erhorn A, et al. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features. *Haematologica* 2013; **98**: 1081-8. doi: 10.3324/haematol.2013.085175
34. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature* 2007; **446**: 758-64. doi: 10.1038/nature05690
35. Kim M, Choi JE, She CJ, Hwang SM, Shin HY, Ahn HS, et al. PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia. *Blood Cells, Mol Dis* 2011; **47**: 62-6. doi: 10.1016/j.bcmd.2011.04.003
36. Kawamata N, Ogawa S, Zimmermann M, Sanada M, Hemminki K, Yamamoto G, et al. Rearrangement and deletion of the PAX5 gene in pediatric acute B-cell lineage lymphoblastic leukemia. *Blood* 2007; **110**: 981. doi: 10.1182/blood.V110.11.981.981
37. Kim M, Choi JE, She CJ, Hwang SM, Shin HY, Ahn HS, et al. PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia. *Blood Cells, Mol Dis* 2011; **47**: 62-6. doi: 10.1016/j.bcmd.2011.04.003
38. Paulsson K, Johansson B. High Hyperdiploid childhood acute lymphoblastic leukemia. *Genes Chromosom Cancer* 2009; **48**: 637-60. doi: 10.1002/gcc.20671
39. Palmi C, Vendramini E, Silvestri D, Longinotti G, Frison D, Cario G, et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. *Leukemia* 2012; **26**: 2245-53. doi: 10.1038/leu.2012.101